Both medications were initially developed to treat type 2 diabetes, but clinical results showing dramatic weight reductions sparked their evolution into tools for obesity management
GLP-1, GIP & Inflammation: What These Medications Really Do and What They Dont Joshua Silva, MD Dec 5, 2025 7 min read Updated: Jan 27 Medically authored by Joshua Silva, MD | Evidence-Based Weight Loss at Potere Health MD Quick Answer GLP-1 and GLP-1/GIP medications (such as semaglutide and tirzepatide ) can lower metabolic inflammation by improving insulin resistance, reducing visceral fat, and lowering inflammatory biomarkers such as C-reactive protein (CRP) ., They can also improve cardiometabolic risk markers (e.g., blood pressure) and, for tirzepatide, can improve atherogenic lipoprotein measures including apoB and triglyceride-rich lipoproteins in clinical research settings., They do not treat autoimmune diseases or fibromyalgia directly
NICE guidance (TA875) recommends that Wegovy treatment in England is initiated within specialist weight management services, with ongoing monitoring and support
Serious Side Effects When to Act Important
[PMID: 32138190] PubMed record related to this compound for laboratory literature review